Immunic’s Patent Milestone for Vidofludimus Calcium in MS

Immunic Achieves Patent Allowance for Vidofludimus Calcium

Immunic, Inc. (Nasdaq: IMUX), a leading biotechnology firm, has recently marked a significant milestone by receiving a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application focused on the use of vidofludimus calcium, particularly in the treatment of progressive multiple sclerosis (PMS). This marks the fifth U.S. patent the company has secured regarding vidofludimus calcium.

Details of the Patent Application

The granted patent, identified as application number 18/529,946, is pivotal as it covers specific dose strengths of vidofludimus calcium. The patent specifies a daily dosage ranging from approximately 10 mg to 45 mg aimed at treating PMS, which includes primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS). With the patent expected to offer protection until 2041, it opens avenues for potential extensions, enhancing the exclusive market rights for Immunic’s innovative treatment options.

Significance of Patent Allowance

Dr. Daniel Vitt, CEO of Immunic, expressed that this key patent allowance is a remarkable advancement for their vidofludimus calcium initiative in PMS. It is a timely expansion, achieved soon after the promising results from their phase 2 CALLIPER trial, which demonstrated the drug's neuroprotective abilities. Importantly, the trial showed a reduction in the time to disability worsening, reinforcing vidofludimus calcium’s potential to slow the progression of MS, enhancing patient outcomes.

Insights from CALLIPER Trial Results

The CALLIPER trial evidenced that vidofludimus calcium significantly impedes the deterioration of disability and reduces thalamic brain volume loss. These outcomes not only highlight its efficacy but also support the drug as a viable option for pivotal phase 3 trials. The potential to meet regulatory endpoints strengthens expectations for timely healthcare discussions regarding this promising treatment.

Multi-Layered Patent Protection Strategy

Immunic has strategically fortified its intellectual property landscape through multiple granted patents across various jurisdictions, which encapsulate the composition-of-matter for different salt forms of vidofludimus calcium. This intricate portfolio illustrates a commitment to innovation and a comprehensive approach to protecting its groundbreaking research from competitive threats. The robust patent strategy extends not only to the treatment of MS but also aims to address other neurodegenerative conditions through a pending application that could extend protection up to 2044.

Vidofludimus Calcium: A Unique Treatment Approach

Vidofludimus calcium is not just any drug; it represents a unique investigational therapy especially developed for chronic inflammatory conditions and autoimmune disorders. It leverages a dual mode of action that provides neuroprotective, anti-inflammatory, and antiviral effects, addressing the intricacies of multiple sclerosis treatment. The positive outcomes in trials reinforce its positioning as a promising solution for patients navigating the challenges of this debilitating condition.

About Immunic, Inc.

Founded with a vision for innovation in biotechnology, Immunic, Inc. (Nasdaq: IMUX) is diligently working on its pipeline of orally administered therapies aimed at treating chronic inflammatory and autoimmune diseases. Currently, the company is finalizing phase 3 clinical trials for vidofludimus calcium, with data expected to emerge by 2026. This drug stands out due to its ability to activate the Nurr1 neuroprotective pathway while effectively inhibiting DHODH to combat inflammation and viral activity. Immunic is also exploring additional compounds, including IMU-856 and IMU-381, which target various pathways within gastrointestinal health and diseases.

Frequently Asked Questions

What is the recent milestone achieved by Immunic?

Immunic received a Notice of Allowance for a key patent concerning vidofludimus calcium, enhancing treatment options for progressive multiple sclerosis.

What is vidofludimus calcium?

Vidofludimus calcium is an investigational small molecule drug designed for treating chronic inflammatory and autoimmune diseases, including multiple sclerosis.

How does vidofludimus calcium work?

This drug operates through a dual mode of action, providing neuroprotective benefits while concurrently inhibiting inflammatory responses.

What is the expected duration of patent protection for this drug?

The patent is expected to secure market exclusivity until 2041, with potential extensions available.

What are Immunic's future plans?

Immunic plans to push forward with its phase 3 clinical trials for vidofludimus calcium, aiming to provide innovative solutions for patients with multiple sclerosis.

About The Author

Hi there, I'm Hannah Lewis, a writer and financial specialist of 36 years old committed to making money understandable and approachable to everyone. Years of working in the field have given me a thorough grasp of market trends, investment techniques, and economic fundamentals. My objective is to enable people, by means of understandable, useful guidance, to take charge of their financial destiny.

I have written many articles for financial blogs over my career that simplify difficult financial ideas into understandable insights. Being financially literate is a critical ability, and I am passionate about enabling people to confidently manage their financial lives. Regardless of your level of experience, my work will help you at every stage of the investment process. I appreciate being allowed to share in your success and financial expansion.

Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.